See more : Fuji Corporation Limited (8860.T) Income Statement Analysis – Financial Results
Complete financial analysis of Acorda Therapeutics, Inc. (ACORQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Acorda Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Tronox Holdings plc (TROX) Income Statement Analysis – Financial Results
- Viasat, Inc. (0LPE.L) Income Statement Analysis – Financial Results
- Aerospace CH UAV Co.,Ltd (002389.SZ) Income Statement Analysis – Financial Results
- Want Want China Holdings Limited (WWNTF) Income Statement Analysis – Financial Results
- Schroder UK Mid Cap Fund plc (SCP.L) Income Statement Analysis – Financial Results
Acorda Therapeutics, Inc. (ACORQ)
About Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 117.63M | 118.57M | 129.07M | 152.97M | 192.41M | 471.43M | 588.29M | 519.60M |
| Cost of Revenue | 46.05M | 61.10M | 71.55M | 64.28M | 60.49M | 99.31M | 135.71M | 108.11M |
| Gross Profit | 71.59M | 57.47M | 57.52M | 88.69M | 131.92M | 372.12M | 452.57M | 411.49M |
| Gross Profit Ratio | 60.86% | 48.47% | 44.56% | 57.98% | 68.56% | 78.93% | 76.93% | 79.19% |
| Research & Development | 5.15M | 5.80M | 9.82M | 22.71M | 58.68M | 105.17M | 160.56M | 203.44M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 89.70M | 105.96M | 119.00M | 152.53M | 189.85M | 179.95M | 182.45M | 217.84M |
| Other Expenses | 51.00K | 1.25M | -6.00K | 167.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 94.85M | 111.76M | 128.82M | 175.25M | 248.53M | 285.12M | 343.01M | 421.27M |
| Cost & Expenses | 140.90M | 172.86M | 200.37M | 239.52M | 309.01M | 384.43M | 478.73M | 529.38M |
| Interest Income | 530.00K | 1.91M | 5.00K | 816.00K | 4.17M | 3.52M | 136.00K | 339.00K |
| Interest Expense | 31.53M | 30.20M | 30.04M | 30.57M | 21.87M | 21.60M | 18.66M | 16.53M |
| Depreciation & Amortization | 31.67M | 32.81M | 33.95M | 41.30M | 34.57M | 11.48M | 36.10M | 21.58M |
| EBITDA | -232.82M | -21.48M | -45.09M | -35.80M | -217.80M | 53.50M | -209.46M | -4.16M |
| EBITDA Ratio | 7.14% | -18.12% | -28.93% | -29.59% | -42.63% | 20.89% | 24.76% | 2.27% |
| Operating Income | -23.26M | -54.29M | -71.30M | -86.55M | -116.61M | 87.00M | 109.56M | -9.78M |
| Operating Income Ratio | -19.78% | -45.79% | -55.24% | -56.58% | -60.60% | 18.45% | 18.62% | -1.88% |
| Total Other Income/Expenses | -272.76M | 19.04M | -37.78M | -21.11M | -157.64M | -66.58M | -361.45M | -32.49M |
| Income Before Tax | -296.02M | -35.25M | -109.07M | -107.67M | -274.25M | 20.42M | -251.89M | -42.27M |
| Income Before Tax Ratio | -251.65% | -29.73% | -84.51% | -70.39% | -142.53% | 4.33% | -42.82% | -8.13% |
| Income Tax Expense | -43.17M | 30.67M | -5.12M | -8.07M | -1.28M | -13.26M | -28.53M | -6.67M |
| Net Income | -252.85M | -65.92M | -103.95M | -99.59M | -272.97M | 33.68M | -223.36M | -34.62M |
| Net Income Ratio | -214.95% | -55.59% | -80.54% | -65.11% | -141.87% | 7.14% | -37.97% | -6.66% |
| EPS | -203.59 | -66.90 | -195.75 | -246.40 | -689.42 | 85.98 | -582.69 | -91.79 |
| EPS Diluted | -203.59 | -66.90 | -195.75 | -246.40 | -689.42 | 85.38 | -582.69 | -91.79 |
| Weighted Avg Shares Out | 1.24M | 985.35K | 531.05K | 404.20K | 395.93K | 391.75K | 383.32K | 377.16K |
| Weighted Avg Shares Out (Dil) | 1.24M | 985.35K | 531.05K | 404.20K | 395.93K | 394.51K | 383.32K | 377.16K |
Source: https://incomestatements.info
Category: Stock Reports